WHO Consults On Evaluating mRNA Vaccines For Infectious Diseases
Special Considerations Outlined For COVID-19 Vaccines
The World Health Organization says there is a pressing need for guidance on the evaluation of mRNA vaccines because of the rapidity with which clinical trials have progressed for COVID-19 candidate vaccines, their emergency use approval or authorization, and their subsequent widespread use.
You may also be interested in...
The MHRA intends to drop around 300 roles as it faces a financial crunch after leaving the EU and other pressures.
The Association of Contract Research Organizations’ revised toolkit on decentralized trials explains how to deal with data quality and integrity.
The European Medicines Agency has updated its reflection paper on methodologies for comparative quality assessment. The paper clarifies expectations on the assessment of similarity for manufacturing changes and for generic and biosimilar development by introducing the concept of “similarity condition.”